Exact Mass: 452.2464814
Exact Mass Matches: 452.2464814
Found 356 metabolites which its exact mass value is equals to given mass value 452.2464814
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Diphenoxylate
C30H32N2O2 (452.24636519999996)
A meperidine congener used as an antidiarrheal, usually in combination with atropine. At high doses, it acts like morphine. Its unesterified metabolite difenoxin has similar properties and is used similarly. It has little or no analgesic activity. This medication is classified as a Schedule V under the Controlled Substances Act by the Food and Drug Administration (FDA) and the DEA in the United States when used in preparations. When diphenoxylate is used alone, it is classified as a Schedule II. A - Alimentary tract and metabolism > A07 - Antidiarrheals, intestinal antiinflammatory/antiinfective agents > A07D - Antipropulsives > A07DA - Antipropulsives D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics C78276 - Agent Affecting Digestive System or Metabolism > C266 - Antidiarrheal Agent D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D005765 - Gastrointestinal Agents > D000930 - Antidiarrheals
Rhodojaponin I
(14alpha,17beta,20S,22R)-14,20-Epoxy-17-hydroxy-1-oxowitha-3,5,24-trienolide
(14alpha,17beta,20S,22R)-14,20-Epoxy-17-hydroxy-1-oxowitha-3,5,24-trienolide is found in fruits. (14alpha,17beta,20S,22R)-14,20-Epoxy-17-hydroxy-1-oxowitha-3,5,24-trienolide is a constituent of Physalis peruviana (Cape gooseberry) Constituent of Physalis peruviana (Cape gooseberry). (14alpha,17beta,20S,22R)-14,20-Epoxy-17-hydroxy-1-oxowitha-3,5,24-trienolide is found in fruits.
Tafluprost
C25H34F2O5 (452.23741780000006)
Tafluprost is only found in individuals that have used or taken this drug. It is a prostaglandin analogue used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension. Tafluprost was approved for use in the U.S. on February 10, 2012.Tafluprost is a prostaglandin F2a analogue. Specifically, Tafluprost is a prostanoid selective FP receptor agonist that is believed to reduce the intraocular pressure (IOP) by increasing the outflow of aqueous humor. Studies in animals and man suggest that the main mechanism of action is increased uveoscleral outflow. S - Sensory organs > S01 - Ophthalmologicals > S01E - Antiglaucoma preparations and miotics > S01EE - Prostaglandin analogues C78568 - Prostaglandin Analogue
PA(10:0/8:0)
C21H41O8P (452.25389160000003)
PA(10:0/8:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(10:0/8:0), in particular, consists of one chain of capric acid at the C-1 position and one chain of caprylic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(8:0/10:0)
C21H41O8P (452.25389160000003)
PA(8:0/10:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(8:0/10:0), in particular, consists of one chain of caprylic acid at the C-1 position and one chain of capric acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
[(1S,2R,4aR,8aR)-1-acetyloxy-1,4a-dimethyl-6-oxo-7-propan-2-ylidene-2,3,4,5,8,8a-hexahydronaphthalen-2-yl] 3-acetyloxy-2-hydroxy-2-methylbutanoate
2-Picenecarboxylic acid
(20R,22R)-21,24-epoxy-5beta-hydroxy-1-oxowitha-2,9(11),25(27)-trienolide|withametelinol-A
2??,5??,9??-Trihydroxy-10??,13??-diacetoxy-4??,20-epoxytaxa-11-ene
(15R)-scutecyprol A|15beta-scutecyprol A|15R-scutecyprol A|clerodin hemiacetal
(2beta,3beta,5alpha,6alpha)-2,3-bis(acetyloxy)-8,13-epoxy-6,9-dihydroxylabd-14-en-11-one|(3R,4aR,6S,6aS,8R,9S,10aS,10bS)-8,9-bis(acetyloxy)-3-ethenyldodecahydro-6,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1H-naphtho[2,1-b]pyran-1-one|excolabdone A
7alpha,12alpha,14beta,15beta-tetrahydroxy-3beta,19-diacetoxy-ent-kaur-16-ene|pharicinin D
3beta,6alpha,11beta,15beta-tetrahydroxy-1alpha,7beta-diacetoxy-ent-kaur-16-ene|nervonin F
1alpha,3beta,6alpha,15beta-tetrahydroxy-7beta,11beta-diacetoxy-ent-kaur-16-ene|nervonin I
(1alpha,5alpha,6beta,7beta)-1,6-bis(acetyloxy)-8,13-epoxy-7,9-dihydroxylabd-14-en-11-one|(3R,4aR,5S,6S,6aS,10S,10aR,10bS)-6,10-bis(acetyloxy)-3-ethenyldodecahydro-5,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1H-naphtho[2,1-b]pyran-1-one|excolabdone B
antidesmanin E|antidesmanin F|erythro-4-(2-(2-methoxy-4-((E)-3,3-dimethylpenta-1,4-dienyl)phenoxy)-1-hydroxy-3,3-dimethylpent-4-enyl)-2-methoxyphenol|threo-4-(2-(2-methoxy-4-((E)-3,3-dimethylpenta-1,4-dienyl)phenoxy)-1-hydroxy-3,3-dimethylpent-4-enyl)-2-methoxyphenol
(20R,22R)-17beta-hydroxy-1,12-dioxowitha-2,5,24-trien-26,22-olide|jaborosalactone 44
9alpha,10beta-diacetoxy-2alpha,5alpha,14beta-trihydroxy-4,20-epoxy,11-taxene
3-epi-14,15-dihydrocaryoptinol|3beta-hydroxy-14,15-dihydroclerodin|ajubractin E
7beta,11alpha-diacetoxy-8,13-epoxy-6beta,9alpha-dihydroxylabd-14-ene-1-one|coleoforskolin
(3R,4S,5R,6R,2R,3S)-3-O-(2,3-diacetoxy-2-methylbutyryl)cuauhtemone
1-[11-(ferulyloxy)undecanoyl]glycerol|2,3-dihydroxypropyl 11-{[(2E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]oxy}undecanoate
24,25,26,27-tetra-norapotirucalla-(apoeupha)-6alpha-acetoxy-7alpha-hydroxy-1,14,20,22-tetraen-21,23-epoxy-3-one|6alpha-O-acetyl-7-deacetylnimocinol
(22R)-4beta,27-dihydroxy-1-oxo-witha-2,5,16,24-tetraenolide|(4S,20S,22R)-4,27-dihydroxy-1-oxo-witha-2,5,16,24-tetraenolide
(20R,22R)-14,20-Dihydroxy-1-oxowitha-2,5,16,22-tetraenolide
3,22beta-dihydroxy-24,29-dinor-1(10),3,5-friedelatriene-2,7,21-trione
(22R,Z)-16beta,27-dihydroxy-1-oxo-witha-2,5,17(20),24-tetraenolide
3,7,9-trihydroxy-4,6a,6b,8a,11,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydropicene-2,10-dione
(20R,22R)-14,20-Dihydroxy-1-oxowitha-2,4,6,24-tetraenolide|14alpha,20alphaF-dihydroxy-1-oxo-22R-witha-2,4,6,24-tetraenolide
16-en-27-deoxywithaferin A|27-deoxy-Delta(16)-withaferin A|5beta,6beta-epoxy-4beta-hydroxy-1-oxo-witha-2,16,24-trienolide
1-(18-hydroxyoleoyl)-sn-glycrol 3-phosphate
C21H41O8P (452.25389160000003)
Diphenoxylate
C30H32N2O2 (452.24636519999996)
A - Alimentary tract and metabolism > A07 - Antidiarrheals, intestinal antiinflammatory/antiinfective agents > A07D - Antipropulsives > A07DA - Antipropulsives D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics C78276 - Agent Affecting Digestive System or Metabolism > C266 - Antidiarrheal Agent D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D005765 - Gastrointestinal Agents > D000930 - Antidiarrheals
C28H36O5_2-Picenecarboxylic acid, 1,2,3,4,4a,5,6,6a,8,12b,13,14,14a,14b-tetradecahydro-10,11-dihydroxy-2,4a,6a,12b,14a-pentamethyl-8-oxo-, (2R,4aS,6aS,12bR,14aS,14bR)
C24H36O8_Butanoic acid, 3-(acetyloxy)-2-hydroxy-2-methyl-, (1S,2R,4aR,8aR)-1-(acetyloxy)decahydro-1,4a-dimethyl-7-(1-methylethylidene)-6-oxo-2-naphthalenyl ester
(2R,4aS,6aR,6aS,14aS,14bR)-10,11-dihydroxy-2,4a,6a,6a,14a-pentamethyl-8-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylic acid
[(1S,2R,4aR,8aR)-1-acetyloxy-1,4a-dimethyl-6-oxo-7-propan-2-ylidene-2,3,4,5,8,8a-hexahydronaphthalen-2-yl] 3-acetyloxy-2-hydroxy-2-methylbutanoate_major
b-D-Glucopyranosiduronic acid, (3a,5b)-17-oxoestran-3-yl
b-D-Glucopyranosiduronic acid, (3b,5a)-17-oxoestran-3-yl
b-D-Glucopyranosiduronic acid, (3b,5b)-17-oxoestran-3-yl
His Ile Pro Ser
His Ile Ser Pro
His Leu Pro Ser
His Leu Ser Pro
His Pro Ile Ser
His Pro Leu Ser
His Pro Ser Ile
His Pro Ser Leu
His Pro Thr Val
His Pro Val Thr
His Ser Ile Pro
His Ser Leu Pro
His Ser Pro Ile
His Ser Pro Leu
His Thr Pro Val
His Thr Val Pro
His Val Pro Thr
His Val Thr Pro
Ile His Pro Ser
Ile His Ser Pro
Ile Pro His Ser
Ile Pro Ser His
Ile Ser His Pro
Ile Ser Pro His
Leu His Pro Ser
Leu His Ser Pro
Leu Pro His Ser
Leu Pro Ser His
Leu Ser His Pro
Leu Ser Pro His
Pro His Ile Ser
Pro His Leu Ser
Pro His Ser Ile
Pro His Ser Leu
Pro His Thr Val
Pro His Val Thr
Pro Ile His Ser
Pro Ile Ser His
Pro Leu His Ser
Pro Leu Ser His
Pro Ser His Ile
Pro Ser His Leu
Pro Ser Ile His
Pro Ser Leu His
Pro Thr His Val
Pro Thr Val His
Pro Val His Thr
Pro Val Thr His
Ser His Ile Pro
Ser His Leu Pro
Ser His Pro Ile
Ser His Pro Leu
Ser Ile His Pro
Ser Ile Pro His
Ser Leu His Pro
Ser Leu Pro His
Ser Pro His Ile
Ser Pro His Leu
Ser Pro Ile His
Ser Pro Leu His
Thr His Pro Val
Thr His Val Pro
Thr Pro His Val
Thr Pro Val His
Thr Val His Pro
Thr Val Pro His
Val His Pro Thr
Val His Thr Pro
Val Pro His Thr
Val Pro Thr His
Val Thr His Pro
Val Thr Pro His
Tafluprost
C25H34F2O5 (452.23741780000006)
S - Sensory organs > S01 - Ophthalmologicals > S01E - Antiglaucoma preparations and miotics > S01EE - Prostaglandin analogues C78568 - Prostaglandin Analogue
octadecanoic acid-1,2,2,2-tetrafluoro-1-(trifluoromethyl)ethyl ester
(14alpha,17beta,20S,22R)-14,20-Epoxy-17-hydroxy-1-oxowitha-3,5,24-trienolide
GDC-0349
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2201 - mTOR Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor GDC-0349 is a potent and selective ATP-competitive mTOR inhibitor with a Ki of 3.8 nM. GDC-0349 inhibits of both mTORC1 and mTORC2 complexes. GDC-0349 is a potent and selective ATP-competitive mTOR inhibitor with a Ki of 3.8 nM. GDC-0349 inhibits of both mTORC1 and mTORC2 complexes.
Bofutrelvir
COVID info from PDB, Protein Data Bank, clinicaltrial, clinicaltrials, clinical trial, clinical trials C254 - Anti-Infective Agent > C281 - Antiviral Agent C471 - Enzyme Inhibitor > C783 - Protease Inhibitor Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Paraminabeolide F
A withanolide that is 18,22:23,26-diepoxyergosta-1,4-diene substituted by oxo groups at positions 3, 18 and 26. It has been isolated from a Formosan soft coral Paraminabea acronocephala.
[(2R)-2-hydroxy-3-phosphonooxypropyl] (Z)-18-hydroxyoctadec-9-enoate
C21H41O8P (452.25389160000003)
[(1S,3S,4R,6R,8S,9S,10R,11R,14R,15R,17R)-17-acetyloxy-4,10,15-trihydroxy-5,5,10,15-tetramethyl-7-oxapentacyclo[12.2.1.01,11.04,9.06,8]heptadecan-3-yl] acetate
(2S,3S,3aR,9bR)-7-[3-[dimethylamino(oxo)methyl]phenyl]-1-ethyl-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
(2R,3R,3aS,9bS)-7-[3-[dimethylamino(oxo)methyl]phenyl]-1-ethyl-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridin-2-ylacetamide
N-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridin-2-ylacetamide
N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridin-2-ylacetamide
N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridin-2-ylacetamide
N-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridin-2-ylacetamide
N-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridin-2-ylacetamide
N-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridin-2-ylacetamide
N-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridin-2-ylacetamide
(1-Acetyloxy-3-phosphonooxypropan-2-yl) hexadecanoate
C21H41O8P (452.25389160000003)
(2-Nonanoyloxy-3-phosphonooxypropyl) nonanoate
C21H41O8P (452.25389160000003)
(1-Phosphonooxy-3-propanoyloxypropan-2-yl) pentadecanoate
C21H41O8P (452.25389160000003)
(1-Hexanoyloxy-3-phosphonooxypropan-2-yl) dodecanoate
C21H41O8P (452.25389160000003)
(1-Butanoyloxy-3-phosphonooxypropan-2-yl) tetradecanoate
C21H41O8P (452.25389160000003)
(1-Heptanoyloxy-3-phosphonooxypropan-2-yl) undecanoate
C21H41O8P (452.25389160000003)
(1-Pentanoyloxy-3-phosphonooxypropan-2-yl) tridecanoate
C21H41O8P (452.25389160000003)
(1-Octanoyloxy-3-phosphonooxypropan-2-yl) decanoate
C21H41O8P (452.25389160000003)
[(2R)-2-octanoyloxy-3-phosphonooxypropyl] decanoate
C21H41O8P (452.25389160000003)
phosphatidic acid 18:0
C21H41O8P (452.25389160000003)
A phosphatidic acid in which the two acyl groups contain a total of 18 carbons and no double bonds.
GSK3326595
GSK3326595 is a protein arginine methyltransferase 5 (PRMT5) inhibitor. GSK3326595 decreases SARS-CoV-2 infection, inhibits cancer cell proliferation and induces pro-inflammatory macrophage polarization and increases hepatic triglyceride levels without affecting atherosclerosis. GSK3326595 can be used for research of relapsed/refractory mantle cell lymphoma[1][2][3][4][5].
(1r,2r,8s,10r,11r,15r,16s)-15-(furan-3-yl)-2,7,7,11,16-pentamethyl-5-oxo-6-oxatetracyclo[9.7.0.0²,⁸.0¹²,¹⁶]octadeca-3,12-dien-10-yl acetate
(1r,5r,8r)-8-[(1r,3as,3bs,5as,9ar,11as)-5a-hydroxy-9a,11a-dimethyl-9-oxo-1h,2h,3h,3ah,3bh,4h,5h,6h,11h-cyclopenta[a]phenanthren-1-yl]-5-methyl-4-methylidene-2,6-dioxabicyclo[3.3.1]nonan-3-one
(1s,2r,4r,6r,7s,10r,11r,16r,18r)-6-(furan-3-yl)-1,7,11,15,15-pentamethyl-14-oxo-3-oxapentacyclo[8.8.0.0²,⁴.0²,⁷.0¹¹,¹⁶]octadec-12-en-18-yl acetate
(1r,2r,3r,4s,6s,9s,10s,11s,13s,14s,16s)-6-(acetyloxy)-2,16-dihydroxy-13-(hydroxymethyl)-5,5,9-trimethyl-12-oxapentacyclo[11.2.1.1¹¹,¹⁴.0¹,¹⁰.0⁴,⁹]heptadecan-3-yl acetate
(1s,2r,4s,8r,9r,10s,14s,15r)-9-(acetyloxy)-2-hydroxy-1,10,14-trimethyl-5-methylidene-6-oxo-7,18-dioxatricyclo[13.2.1.0⁴,⁸]octadecan-14-yl acetate
8-(acetyloxy)-3,6,11,15-tetrahydroxy-5,5,9-trimethyl-14-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-2-yl acetate
6-(1-{3a-hydroxy-9a,11a-dimethyl-9-oxo-3h,3bh,4h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}-1-hydroxyethyl)-3,4-dimethyl-5,6-dihydropyran-2-one
1-(furan-2-yl)-4-hydroxy-3b,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-5-yl acetate
(2r,4as,6as,12br,14as,14br)-10,11-dihydroxy-2,4a,6a,12b,14a-pentamethyl-8-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylic acid
(1s,2s,6s,7s,9r,13r,14s,15r,16s,17r)-11,14-dihydroxy-4,15-dimethoxy-2,6,14,17-tetramethyl-3-oxo-10-oxatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadec-4-en-16-yl acetate
(1r,3as,3br,9ar,9bs,11as)-1-[(1r)-1-[(2r)-4,5-dimethyl-6-oxo-2,3-dihydropyran-2-yl]ethyl]-1-hydroxy-9a,11a-dimethyl-2h,3h,3ah,3bh,4h,6h,9bh,10h-cyclopenta[a]phenanthrene-9,11-dione
6-(1-{6-hydroxy-9a,11a-dimethyl-9-oxo-3h,3ah,3bh,4h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}ethyl)-3-(hydroxymethyl)-4-methyl-5,6-dihydropyran-2-one
11,14-dihydroxy-4,15-dimethoxy-2,6,14,17-tetramethyl-3-oxo-10-oxatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadec-4-en-16-yl acetate
(1s,2r,7s,9r,11s,12s,15r,16s)-2,16-dimethyl-15-[(1s,4r,5r)-1-methyl-8-methylidene-7-oxo-2,6-dioxabicyclo[3.3.1]nonan-4-yl]-8-oxapentacyclo[9.7.0.0²,⁷.0⁷,⁹.0¹²,¹⁶]octadec-4-en-3-one
6-(acetyloxy)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-hexahydro-2h-naphtho[2,1-b]pyran-5-yl acetate
[4-(acetyloxy)-5-hydroxy-5-(hydroxymethyl)-1,2-dimethyl-1-[2-(5-oxo-2h-furan-3-yl)ethyl]-hexahydro-2h-naphthalen-4a-yl]methyl acetate
4-[(1r,2r)-2-[4-(3,3-dimethylpenta-1,4-dien-1-yl)-2-methoxyphenoxy]-1-hydroxy-3,3-dimethylpent-4-en-1-yl]-2-methoxyphenol
3,10,11-trihydroxy-4,6b,8a,11,12b,14a-hexamethyl-8,10,12,12a,13,14-hexahydro-7h-picene-2,9-dione
(1s,3br,4r,5ar,9ar,9br,11s,11as)-1-(furan-3-yl)-4-hydroxy-3b,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-11-yl acetate
(1r,2r,3r,4s,6s,9r,10s,11s,13s,14s,16s)-6-(acetyloxy)-2,16-dihydroxy-13-(hydroxymethyl)-5,5,9-trimethyl-12-oxapentacyclo[11.2.1.1¹¹,¹⁴.0¹,¹⁰.0⁴,⁹]heptadecan-3-yl acetate
10-(acetyloxy)-3-ethenyl-5,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-hexahydro-2h-naphtho[2,1-b]pyran-6-yl acetate
17β-hydroxy-14α,20α-epoxy-1-oxo-(22r)-witha-3,5,24-trienolide
{"Ingredient_id": "HBIN001994","Ingredient_name": "17\u03b2-hydroxy-14\u03b1,20\u03b1-epoxy-1-oxo-(22r)-witha-3,5,24-trienolide","Alias": "NA","Ingredient_formula": "C28H36O5","Ingredient_Smile": "CC1=C(C(=O)OC(C1)C2(C3(CCC4(C3(CCC5C4CC=C6C5(C(=O)CC=C6)C)C)O2)O)C)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "10091","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
2alpha,5alpha,9alpha-trihydroxy-10beta,13alpha-diacetoxy-4beta,20-epoxytaxa-11-ene
{"Ingredient_id": "HBIN005247","Ingredient_name": "2alpha,5alpha,9alpha-trihydroxy-10beta,13alpha-diacetoxy-4beta,20-epoxytaxa-11-ene","Alias": "2\u03b1,5\u03b1,9\u03b1-trihydroxy-10\u03b2,13\u03b1-diacetoxy-4\u03b2,20-epoxytaxa-11-ene","Ingredient_formula": "C24H36O8","Ingredient_Smile": "CC1=C2C(C(C3(CCC(C4(C3C(C(C2(C)C)CC1OC(=O)C)O)CO4)O)C)O)OC(=O)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "32118;21688","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
5β,6β-epoxy-4β-hydroxy-1-oxowitha-2,14,24-trienolide
{"Ingredient_id": "HBIN011454","Ingredient_name": "5\u03b2,6\u03b2-epoxy-4\u03b2-hydroxy-1-oxowitha-2,14,24-trienolide","Alias": "NA","Ingredient_formula": "C28H36O5","Ingredient_Smile": "CC12CC=C3C(C1CCC2C4COC5(CC4OC(=O)C5=C)C)CCC6(C3(C(=O)C=CC6)C)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "7127","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
5β,6β-epoxy-4β-hydroxy-1-oxo-witha-2,16,24-trienolide
{"Ingredient_id": "HBIN011455","Ingredient_name": "5\u03b2,6\u03b2-epoxy-4\u03b2-hydroxy-1-oxo-witha-2,16,24-trienolide","Alias": "NA","Ingredient_formula": "C28H36O5","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "7128","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
6α-o-acetyl-7-deacetylnimocinol
{"Ingredient_id": "HBIN012215","Ingredient_name": "6\u03b1-o-acetyl-7-deacetylnimocinol","Alias": "NA","Ingredient_formula": "C28H36O5","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "364","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
benzoylramanone
{"Ingredient_id": "HBIN017830","Ingredient_name": "benzoylramanone","Alias": "NA","Ingredient_formula": "C28H36O5","Ingredient_Smile": "CC(=O)C1CCC2(C1(C(CC3C2CC=C4C3(CCC(C4)O)C)OC(=O)C5=CC=CC=C5)C)O","Ingredient_weight": "452.6 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "2268","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "101974123","DrugBank_id": "NA"}